Engineered probiotic bacteria sense glucose and lower blood sugar in rodents and primates

Researchers engineered an oral probiotic with a glucose-responsive synthetic circuit that couples the HexR transcriptional regulator to a custom promoter. When administered, the bacteria colonize the intestine briefly and trigger expression of therapeutic transgenes, including GLP-1, in response to elevated glucose. Experiments in multiple diabetic mouse strains and in db/db monkeys showed significant reductions in fasting blood glucose, improved lipid parameters, and attenuation of hepatic, renal and inflammatory pathology.

The probiotic was encapsulated for stability, demonstrated limited systemic spread, and elicited no major immune reactions. Data suggest a programmable, non-transplantable platform for real-time metabolic therapy. The work was funded by Chinese national science foundations and the Shanghai municipal science commission.